A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1024 participants.

Also called NCT06221969

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 1,024 participants (enrolled count) (from the registry)
Sponsor
  • Novo Nordisk Registry lists this organization as the lead sponsor
Registry
  • NCT NCT06221969
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States, Argentina, Australia, Canada, Colombia, India, South Africa, Taiwan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT06221969. Randomized; no masking; primary purpose treatment. Start 2024-01-16 (actual); primary completion 2026-03-04 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
Intervention (Drug)
Cagrilintide
Intervention (Drug)
Semaglutide
Intervention (Drug)
Tirzepatide
Lead sponsor
Novo Nordisk A/S (class: industry)

Record details

Record id
cardio:ct-nct06221969
Content hash
25738cea7a2c2d76c10bc4c66628e31424873e406c64243a63286e0c72d81ed5